ADVANCED MATERIALS | 2019
Constrained nanoparticles deliver siRNA and sgRNA to T cells in vivo without targeting ligands.
Using DNA barcoding, nanoparticles that deliver nucleic acids to T cells were identified. Until this report, T cells had only been targeted with nanoparticles coated with antibodies, aptamers, or other targeting ligands. By contrast, our nanoparticles delivered RNA to T cells with simple lipids, which are safer and easier to manufacture.
SCIENTIFIC AMERICAN | 2019
Could the Next Big Information Technology Be ... DNA? How DNA is used to store—and generate-information at extreme scales
In this piece, Guide co-founder James Dahlman describes how DNA can be used to store information. The DNA barcoding process Guide Therapeutics uses to efficiently create safer gene therapies is highlighted.
NANO LETTERS | 2018
A direct comparison of in vitro and in vivo nucleic acid delivery mediated by hundreds of nanoparticles reveals a weak correlation
In this report, in vitro nanoparticle delivery (drug delivery in cell culture) is found not to predict in vivo nanoparticle delivery (drug delivery in a living animal). This is important because historically, almost all nanoparticles are tested in vitro before they are selected for in vivo testing. These data highlight the importance of testing thousands of nanoparticles directly in vivo, a process that is being pioneered at Guide.
ADVANCED MATERIALS | 2019
Nanoparticles Containing Oxidized Cholesterol Deliver mRNA to the Liver Microenvironment at Clinically Relevant Doses
Using DNA barcoding, nanoparticles that deliver mRNA to macrophages and endothelial cells within the liver are identified. This paper demonstrates that chemical modifications to cholesterol within nanoparticles can enhance their efficacy. These LNPs delivered mRNA at doses as low as 0.05 mg / kg.
JACS | 2018
Nanoparticles That Deliver RNA to Bone Marrow Identified by in Vivo Directed Evolution
Using DNA barcoding, nanoparticles that deliver siRNA to bone marrow endothelial cells are identified. This paper includes two important scientific advances. First, bone marrow endothelial cells had not been efficiently targeted by nanoparticles before. Second, the paper utilizes iterative nanoparticle barcoding; the chemical structures that promoted nanoparticle delivery in the first experiment informed the design of nanoparticles in the second experiment.
PNAS | 2018
High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing
In this report, a DNA barcoding technology called ‘FIND’, which enables Guide to measure how hundreds of nanoparticles functionally deliver mRNA into the cytoplasm of target cells, is described. Using this approach, a LNP that delivers mRNA to splenic endothelial cells is discovered. This LNP co-delivers Cas9 mRNA and sgRNA, leading to CRISPR gene editing outside the liver.
ACS NANO | 2018
Analyzing 2,000 in vivo drug delivery data points reveals cholesterol structure impacts nanoparticle delivery
In this report, nanoparticles formulated with many different cholesterols are tested for their ability to deliver nucleic acids in vivo using DNA barcodes. A nanoparticle that delivers siRNA to liver endothelial cells is identified.
DNA barcoding named Top 10 Emerging Technologies by World Economic Forum
Atlanta, GA (September 25, 2019) – DNA barcoding methods developed in the lab of Georgia Tech Professor James Dahlman, and licensed to Guide Therapeutics, Inc. (GuideTx), were named a Top 10 Emerging Technology by the World Economic Forum. GuideTx utilizes this DNA barcoding approach to develop lipid nanoparticles that deliver therapeutic nucleic acids for gene therapies.
James Dahlman, Co-Founder and Board Member of GuideTx stated, “We are honored by this World Economic Forum recognition. We believe our patented DNA barcoding approach has the potential to create drugs in cell types that have been inaccessible to gene therapists.” Read more
FOR MORE INFORMATION CONTACT:
GreatPoint Ventures Invests In Leading Gene Therapy Delivery Platform
Atlanta, GA (March 1, 2019) – GreatPoint Ventures, a leading San Francisco based venture capital firm, announced the closing of an investment in Guide Therapeutics, Inc. (GuideTx), a developer of lipid nanoparticles (LNPs) that deliver therapeutics for gene therapy. GuideTx was organized around the work of Georgia Tech Professor James E. Dahlman.
Professor Dahlman is faculty in the Department of Biomedical Engineering at Georgia Institute of Technology and Emory School of Medicine. Dr. Dahlman was recognized by MIT Technology Review as one of the Top 35 Scientists under 35 for this work. Based upon the work of Dr. Dahlman, GuideTx is able to screen thousands of LNPs in vivo to identify LNPs that deliver RNA to non-liver cell types. GuideTx’s technology has identified nanoparticles that have shown functional delivery to non-liver cell types, greatly extending the potential for treating genetic disease.
Andrew Perlman, Managing Partner at GreatPoint Ventures stated, “GreatPoint has been fortunate to seal a partnership with GuideTx, which promises to be a major player in the next generation of gene therapy utilizing its proprietary ability to develop drugs that can selectively target non-liver cell types. We are confident that Guide will be one of the top players in the rapidly emerging field of gene therapy.”
FOR MORE INFORMATION CONTACT: